Cethromycin
- Generic Name
- Cethromycin
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C42H59N3O10
- CAS Number
- 205110-48-1
- Unique Ingredient Identifier
- J0086219X6
- Background
Cethromycin is a 3-keto (ketolide) derivative of erythromycin A with an 11,12-carbamate group and an O-6-linked aromatic ring system. Cethromycin represents a joint development effort by Abbott Laboratories, Taisho Pharmaceuticals, and Advanced Life Sciences, intended to be marketed under the trade name Restanza for the treatment of community-acquired pneumonia. However, after completing phase III clinical trials, it was deemed safe but not sufficiently efficacious by the FDA.
Since this time, cethromycin has received FDA orphan drug designations for the prophylactic treatment of anthrax inhalation, plague due to Yersinia pestis, and tularemia due to Francisella tularensis. It has also been investigated, by itself or together with zoliflodacin, for the treatment of gonorrhea, and was recently suggested as a possible treatment for liver-stage Plasmodium sporozoite infection.
- Indication
Cethromycin currently has no FDA-approved indications; it was granted orphan drug designation for the prophylactic treatment of inhalation anthrax in 2007 and for the prophylactic treatment of both plague due to Yersinia pestis and tularemia due to Francisella tularensis in 2009.
- Associated Conditions
- Inhalational Anthrax, Plague caused by Yersinia pestis, Tularemia
- Associated Therapies
- -
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.